Sun, Dec 21, 2014, 2:45 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Hyperion Therapeutics, Inc. (HPTX) Message Board

fields59 9 posts  |  Last Activity: Dec 4, 2014 9:20 PM Member since: Dec 31, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by poonyieta Dec 3, 2014 10:35 PM
    fields59 fields59 Dec 4, 2014 9:20 PM Flag

    Yeah. Don't know why, but I'm not complaining.

  • fields59 fields59 Dec 4, 2014 3:33 AM Flag

    Topical calcineurin inhibitors are also used in eczema, so it's not true that treatment options are currently limited to steroids.

  • fields59 fields59 Nov 23, 2014 5:31 PM Flag

    Great question wolefcane. I rode this from $8 to $24 - in retrospect sold too early but I couldn't find a lot of short-term catalysts for growth. I don't foresee Kerydin being a huge seller and the atopic derm products are a ways away still. The analysts (not that they're a great group to trust) have agreed - current highest price target I can find is $30. We'll see. I'm comfortable watching from the sidelines for now. I suspect we'll see $25 before we see $40, but that's just me.

  • Reply to

    some thoughts

    by fields59 Nov 12, 2014 11:58 PM
    fields59 fields59 Nov 13, 2014 10:59 PM Flag

    Ah yes, I should have taken that into account. Just for fun, a few stocks I'd bet my savings (I *am* betting my savings) will outperform ESV over the next year: STML, AQXP, VSTM.

  • fields59 by fields59 Nov 12, 2014 11:58 PM Flag

    For most of the last 7 years I've been in and out of NE and ESV. I sold the last of my ESV position several months ago and have never been happier. So I guess this is a suggestion that those of you who, like me, were perpetually looking around to the corner to the time when these drillers will be finally recognized, appreciated, and the stock would perform accordingly, just free yourself from this prison. Maybe I've just been lucky with picking winners since leaving ESV, but my mental energy is also no longer spent watching these POS stocks do nothing for ever and ever.

    So if you're newly in ESV and somehow only heard about it when it was in the high-30s, you're a lucky one and maybe it's worth sticking around with a small position. If you're a dividend lover and the 7% is enough to make you happy, then by all means hang in there. If you supplement your income with options, or have been a successful range trader, then good luck to you. If like me however, you are in the stock market to watch your investment grow consistently with some degree of pleasure and if you also do not enjoy hating yourself, I would recommend getting the heck out of here.

  • Reply to

    OvaScience HC Wainright to $40.00.

    by boardwalk97 Nov 11, 2014 12:30 PM
    fields59 fields59 Nov 11, 2014 10:26 PM Flag

    Anyone have access to the report or a summary statement that accompanied the price target and rating?

  • Reply to

    Loaded up on TGTX and LPCN

    by skincher Nov 11, 2014 6:46 PM
    fields59 fields59 Nov 11, 2014 10:09 PM Flag

    A little late to the party but good luck - sure seems to be a bright future ahead for TGTX

  • Reply to

    ESPR Opportunity

    by bigdupree Jul 16, 2014 8:22 AM
    fields59 fields59 Sep 23, 2014 9:29 PM Flag

    Yeah bigdupree I think that's right. The initial assumption was that LDL is a good predictor of cardiac disease, so lower the LDL and reduce mortality. That hasn't proven to be entirely true, but it is true that that is the major physiologic effect of statins, and they sure reduce mortality. Ezetimibe, for example however, lowers cholesterol too but has no effect on mortality, post-MI outcomes, etc. So yeah I think the first goal is to show ETC 1002 lowers cholesterol safely and effectively. Then try to see whether it has a mortality benefit - the burden of proof will be on Esperion, which will cost a lot of dollars. If it does improve mortality though, look out. In the meantime, we'll see what effects the soon-to-be-approved PCSK9 inhibitors have. Those are injections, which is usually a big barrier to uptake. Esperion discusses this on their website - it's good reading.

  • Reply to

    ESPR Opportunity

    by bigdupree Jul 16, 2014 8:22 AM
    fields59 fields59 Sep 22, 2014 11:13 PM Flag

    I agree about the promise of their pipeline and I say that as a shareholder. That said, statins have proven mortality benefit that increasing evidence suggests is not clearly related to their cholesterol-lowering effect. The studies about niacin and statins together, for example, are high-yield reading, as are the recent guidelines that do away with follow-up lipid panel testing after initiation of statin therapy. There is a clear need for alternatives to statins and that's where the promise of ETC 1002 lies. I'm holding because the potential is so great. But there won't be significant use of any new lipid-lowering agent until there's a proven mortality benefit.

    Sentiment: Buy

22.97+0.25(+1.10%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Aegerion Pharmaceuticals, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Linn Co, LLC
NASDAQFri, Dec 19, 2014 3:59 PM EST